Bicara Therapeutics Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission covering the period ended September 30, 2026, disclosing its financial position, risk factors, and clinical development activities centered on its lead product candidate, ficerafusp alfa.
Key Highlights
- Share count: As of November 3, 2026, the company had 66,387,197 shares of common stock outstanding at a par value of $0.0001 per share.
- Filer classification: The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC rules.
- Lead candidate: The filing identifies ficerafusp alfa as the company's primary product candidate and states the business is "highly dependent on the success of ficerafusp alfa."
- Financial losses: The company disclosed that it "has incurred significant financial losses since our inception" and anticipates continuing to incur significant losses for the foreseeable future.
- Capital risk: The filing states that inability to raise capital "when needed, or on acceptable terms" may prevent completion of development and commercialization of ficerafusp alfa.
- CRO reliance: The company disclosed it relies on third parties, including independent clinical investigators and contract research organizations, to conduct preclinical studies and clinical trials.
- Exchange listing: Common stock is registered on NASDAQ:BCAX under commission file number 001-42271.
Bicara Therapeutics: Clinical-Stage Operations and Key Disclosures for Q3 2026
Bicara Therapeutics Inc., a Delaware-incorporated clinical-stage biopharmaceutical company headquartered at 116 Huntington Ave, Suite 703, Boston, Massachusetts 02116, filed its quarterly report covering the three and nine months ended September 30, 2026. According to the filing, the company's operations remain concentrated on the development of ficerafusp alfa, with no revenue-generating commercial products disclosed. The filing includes condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, condensed consolidated statements of operations and comprehensive loss, statements of stockholders' equity, and statements of cash flows for the nine months ended September 30, 2026 and 2025.
The company disclosed a broad set of risk factors specific to its clinical-stage status. Among them, the filing states that "clinical development involves a lengthy and expensive process with uncertain outcomes" and that ficerafusp alfa or any future product candidates "may cause undesirable side effects or have other properties" that could halt development, delay regulatory approval, or limit commercial potential. The filing also notes that regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign authorities are "lengthy, time-consuming and inherently unpredictable." These characterizations are the company's own and are subject to its cautionary language regarding forward-looking statements, which the filing notes involve "known and unknown risks, uncertainties and other factors."
On the subject of third-party dependencies, the filing states the company relies, and expects to continue to rely, on contract research organizations to carry out preclinical studies and clinical trials, warning that if these parties do not meet contractual duties or expected deadlines, regulatory approval or commercialization efforts could be substantially harmed. The filing further acknowledges dependence on future third-party collaborators for discovery, development, and commercialization activities. As an emerging growth company, the registrant has not elected to use the extended transition period for complying with new or revised financial accounting standards.
What Was Disclosed
Bicara Therapeutics submitted its Form 10-Q for the quarterly period ended September 30, 2026, disclosing unaudited condensed consolidated financial statements, management's discussion and analysis, and an extensive set of risk factors related to its clinical-stage operations and reliance on ficerafusp alfa as its sole product candidate.
The filing also covers quantitative and qualitative disclosures about market risk, controls and procedures, legal proceedings, and updated risk factors in Part II. The company confirmed it is not a shell company, has met all filing requirements during the preceding 12 months, and has submitted all required Interactive Data Files electronically as required by Rule 405 of Regulation S-T.



Please wait processing your request...